Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of luspatercept versus placebo for transfusion-dependent anemia in lower-risk myelodysplastic syndromes with ring sideroblasts
NL-OMON47664Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Jan 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) and anaemia comparing Luspatercept with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2017; status: active, not recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on NL-OMON47664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47664.